
    
      Flumatinib + hyper-CVAD (younger than 60):

      Induction therapy: Flumatinib 600mg per day, on an empty stomach; For cycles 1, 3, 5, and 7:
      cyclophosphamide (CTX) 300 mg/m² is given intravenously over 3 h every 12 h for six doses on
      days 1-3; a continuous daily infusion of sodium mercaptoethanesulfonate (Mesna) at 600 mg/m²
      per day for 24h starting 1h before CTX and completed approximately 12h after the final CTX
      dose; doxorubicin 50 mg/m² is given intravenously over 24 h on day 4; vincristine (VCR) 1.4
      mg/m² (Maximum daily dose 2 mg) is intravenously on days 4 and 11; dexamethasone (Dex) 40 mg
      is given intravenously or orally on days 1-4 and days 11-14. For cycles 2, 4, 6, and 8:
      methotrexate (MTX) is given intravenously at 200 mg/m² over 2 h, followed by 800 mg/m² over
      22 h on day 1; cytarabine (Ara-C) 3 g/m² is given intravenously over 3 h every 12 h for four
      doses on days 2-3; citrovorum 50 mg is given intravenously, followed by 15 mg every 6 h for
      eight doses beginning 12 h after MTX completion. Prophylactic intrathecal therapy will be
      given after complete remission.

      Maintenance therapy (given for 2 years): intravenous VCR 1.4 mg/m² on day 1 (Maximum daily
      dose 2 mg), every three months; oral dexamethasone 8mg/m² on days 1-7, every three months;
      oral 6-MP 60mg/m² on days 1-7, every month; oral MTX 20mg/m² on day 8, every month; and daily
      flumatinib at 600 mg. Months 6 and 13 of maintenance were intensification courses of
      hyper-CVAD and flumatinib.

      Flumatinib + dose-adjusted VDCP (fit group, 60 years or older):

      Induction therapy: flumatinib 600mg per day, on an empty stomach; vincristine (VCR)
      1.4mg/m2/d (maximum daily dose 2mg) is given intravenously on day 1, 8, 15, 22; daunorubicin
      (DNR) 30mg/m2/d is given intravenously on day 1, 8, 15, 22 (if blasts of day 15 lower than
      20%, DNR is not needed on day 15 and 22); cyclophosphamide (CTX) 400mg/m2/d is given
      intravenously on day 1,8,15 and 22; Prednisone 60mg/m2/d is given orally every other day for
      day 1-22. Prophylactic intrathecal therapy will be given after complete remission.

      Consolidation therapy: flumatinib 600mg per day; daunorubicin (DNR) 40mg/m2 is given
      intravenously on day 1; cytarabine (Ara-C) 60mg/m2 is given intravenously on day 1-5;
      L-Asparaginasum (L-Asp) 500U/kg is given intravenously on day 6-10. If complete remission
      (CR) on day 28, a consolidation chemotherapy will be given on day 35; if not, we will give it
      as salvage therapy; And if CR is achieved after salvage therapy, another consolidation
      chemotherapy will be given.

      Maintenance therapy (given for 2 years): intravenous VCR 1.4 mg/m² on day 1 (Maximum daily
      dose 2 mg), every three months; oral dexamethasone 8mg/m² on days 1-7, every three months;
      oral 6-MP 60mg/m² on days 1-7, every month; oral MTX 20mg/m² on day 8, every month; and daily
      flumatinib at 600 mg.

      Flumatinib + Prednisone (unfit group, 60 years or older):

      Prephase: Prednisone 60 mg/m2/d po, Day -7 to day -1. Induction therapy: flumatinib 600mg per
      day, on an empty stomach; Prednisone 60 mg/m2 per day day 1-24 and then tapered and stopped
      at day 32.

      Maintenance therapy (given for 2 years): flumatinib 600mg per day.
    
  